GLPG 1972

Drug Profile

GLPG 1972

Alternative Names: GLPG1972; S 201086

Latest Information Update: 31 Jul 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Galapagos NV
  • Developer Galapagos NV; Servier
  • Class Antirheumatics; Small molecules
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Osteoarthritis

Most Recent Events

  • 27 Jul 2017 Galapagos and Servier plans a phase II program for Osteoarthritis
  • 20 Jun 2017 Phase-I clinical trials in Osteoarthritis in USA (PO)
  • 14 Jun 2017 Pharmacodynamics data from preclinical trials in Osteoarthritis presented at the 18th Annual Congress of the European League Against Rheumatism (EULAR-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top